Combination antifibrotic and immunosuppressive therapy in progressive fibrosing ILD
Keywords:
Progressive fibrosing interstitial lung disease, Combination therapy, Antifibrotic agents, Immunosuppression, Systemic sclerosis, Connective tissue disease, Nintedanib, PirfenidoneAbstract
Background: Progressive fibrosing interstitial lung disease is characterized by continuous functional decline and early mortality despite conventional immunosuppressive therapy. The dual pathophysiology involves both inflam-mation and fibrosis and provides rationale for combination antifibrotic and immunosuppressive therapy. Objectives:To review and synthesize current clinical evidence on the efficacy, safety, and clinical positioning of combination antifibrotic and immunosuppressive therapy in progressive fibrosing interstitial lung disease.
Methods: We conducted a comprehensive literature review of randomized controlled trials, observational studies, and real-world cohorts published between 2015 and 2025 that evaluated combined antifibrotic (nintedanib or pirfe-nidone) and immunosuppressive therapy in adults with non-IPF progressive fibrosing ILD. We synthesized evidence from randomized controlled trials, observational studies, and real-world data regarding their methodolo-gies, patient population, therapies and outcomes.
Results: Forty-one studies were identified, including 14 RCTs and 12 observational cohorts. The available evidence suggests that combination therapy demonstrates promising results across various PF-ILDs. Clinical trials and real-world data have shown improved lung function and forced vital capacity with combination therapy in PF-ILD. Evi-dence supports combination therapy to be well-tolerated, with manageable safety and tolerability profile consistent with individual agents rather than additive effects. Limitations of the available evidence include heterogeneity of PF-ILD populations, variable background immunosuppression, and limited long-term outcome data.
Conclusions: Combination antifibrotic and immunosuppressive therapy shows meaningful efficacy in select PF-ILD patients. Evidence supports individualized combination approaches, particularly for progressive systemic sclerosis-ILD and connective tissue disease-ILD with nonspecific interstitial pneumonia pattern. Critical evidence gaps remain regarding optimal sequencing, patient selection, and long-term outcomes, requiring future investigation.
References
1. Flaherty KR, Wells AU, Cottin V, et al. Nintedanib in Progressive Fibrosing Interstitial Lung Diseases. N Engl J Med. 2019;381(18):1718-1727. doi:10.1056/NEJMoa1908681
2. Wells AU, Flaherty KR, Brown KK, et al. Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial. Lancet Respir Med. 2020;8(5):453-460. doi:10.1016/S2213-2600(20)30036-9
3. Huh JY, Lee JH, Song JW. Efficacy and safety of combination therapy with pirfenidone and nintedanib in patients with idiopathic pulmonary fibrosis. Front Pharmacol. 2023;14:1301923. doi:10.3389/fphar.2023.1301923
4. Raghu G, Remy-Jardin M, Richeldi L, et al. Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. Am J Respir Crit Care Med. 2022;205(9):e18-e47. doi:10.1164/rccm.202202-0399ST
5. Raghu G, Montesi SB, Silver RM, et al. Treatment of Systemic Sclerosis-associated Interstitial Lung Disease: Evidence-based Recommendations. An Official American Thoracic Society Clinical Practice Guideline. Am J Respir Crit Care Med. 2024;209(2):137-152. doi:10.1164/rccm.202306-1113ST
6. Maher TM, Tudor VA, Saunders P, et al. Rituximab versus intravenous cyclophosphamide in patients with connective tissue disease-associated interstitial lung disease in the UK (RECITAL): a double-blind, double-dummy, randomised, controlled, phase 2b trial. Lancet Respir Med. 2023;11(1):45-54. doi:10.1016/S2213-2600(22)00359-9
7. Matteson EL, Kelly C, Distler JHW, et al. Nintedanib in Patients With Autoimmune Disease-Related Progressive Fibrosing Interstitial Lung Diseases: Subgroup Analysis of the INBUILD Trial. Arthritis Rheumatol. 2022;74(6):1039-1047. doi:10.1002/art.42075
8. Mankikian J, Caille A, Reynaud-Gaubert M, et al. Rituximab and mycophenolate mofetil combination in patients with interstitial lung disease (EVER-ILD): a double-blind, randomised, placebo-controlled trial. Eur Respir J. 2023;61(6):2202071. doi:10.1183/13993003.02071-2022
9. Tashkin DP, Roth MD, Clements PJ, et al. Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial. Lancet Respir Med. 2016;4(9):708-719. doi:10.1016/S2213-2600(16)30152-7
10. Distler O, Highland KB, Gahlemann M, et al. Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease. N Engl J Med. 2019;380(26):2518-2528. doi:10.1056/NEJMoa1903076
11. Shumar JN, Chandel A, King CS. Antifibrotic Therapies and Progressive Fibrosing Interstitial Lung Disease (PF-ILD): Building on INBUILD. J Clin Med. 2021;10(11):2285. doi:10.3390/jcm10112285
12. Gogali A, Kostikas K, Tzouvelekis A. Initiation of antifibrotic treatment in fibrosing interstitial lung disease: is the clock ticking till proven progression?. Eur Respir Rev. 2025;34(177):250023. doi:10.1183/16000617.0023-2025
13. Tashkin DP, Elashoff R, Clements PJ, et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med. 2006;354(25):2655-2666. doi:10.1056/NEJMoa055120
14. Khanna D, Lin CJF, Furst DE, et al. Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respir Med. 2020;8(10):963-974. doi:10.1016/S2213-2600(20)30318-0
15. Yang M, Tan Y, Yang T, Xu D, Chen M, Chen L. Efficacy and safety of antifibrotic drugs for interstitial lung diseases other than IPF: A systematic review, meta-analysis and trial sequential analysis. PLoS One. 2025;20(2):e0318877. doi:10.1371/journal.pone.0318877
16. Highland KB, Distler O, Kuwana M, et al. Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: a subgroup analysis of the SENSCIS trial. Lancet Respir Med. 2021;9(1):96-106. doi:10.1016/S2213-2600(20)30330-1
17. Renner A, Vertanen E, Sutinen E, Ainola M, Myllärniemi M, Hollmén M. Characterisation of patients with antifibrotic-treated non-idiopathic pulmonary fibrosis progressive pulmonary fibrosis: a retrospective real-life study. BMJ Open. 2025;15(11):e097246. doi:10.1136/bmjopen-2024-097246
18. Khanna D, Albera C, Fischer A, et al. An Open-label, Phase II Study of the Safety and Tolerability of Pirfenidone in Patients with Scleroderma-associated Interstitial Lung Disease: the LOTUSS Trial. J Rheumatol. 2016;43(9):1672-1679. doi:10.3899/jrheum.151322
19. Khanna D, Spino C, Tashkin DP, et al. Combining Pirfenidone With Mycophenolate Mofetil for Systemic Sclerosis-Related Interstitial Lung Disease (Scleroderma Lung Study III): An Investigator-Initiated, Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial. ACR Open Rheumatol. 2025;7(12):e70126. doi:10.1002/acr2.70126
20. Johnson SR, Bernstein EJ, Bolster MB, et al. 2023 American College of Rheumatology (ACR)/American College of Chest Physicians (CHEST) Guideline for the Treatment of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Diseases. Arthritis Care Res (Hoboken). 2024;76(8):1051-1069. doi:10.1002/acr.25348
21. Allanore Y, Khanna D, Smith V, et al. Effects of nintedanib in patients with limited cutaneous systemic sclerosis and interstitial lung disease. Rheumatology (Oxford). 2024;63(3):639-647. doi:10.1093/rheumatology/kead280
22. Allanore Y, Vonk MC, Distler O, et al. Continued treatment with nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from SENSCIS-ON. Ann Rheum Dis. 2022;81(12):1722-1729. doi:10.1136/ard-2022-222564
23. Maher TM, Tudor V, Saunders P, et al. Rituximab versus Cyclophosphamide for the Treatment of Connective Tissue Disease Associated Interstitial Lung Disease (RECITAL): A Sub-group Analysis of a Multi-centre Randomised Controlled Trial [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/rituximab-versus-cyclophosphamide-for-the-treatment-of-connective-tissue-disease-associated-interstitial-lung-disease-recital-a-sub-group-analysis-of-a-multi-centre-randomised-controlled-trial/. Accessed December 15, 2025.
24. Cottin V, Richeldi L, Rosas I, et al. Nintedanib and immunomodulatory therapies in progressive fibrosing interstitial lung diseases. Respir Res. 2021;22(1):84. doi:10.1186/s12931-021-01668-1
25. Inoue Y, Suda T, Kitamura H, et al. Efficacy and safety of nintedanib in Japanese patients with progressive fibrosing interstitial lung diseases: Subgroup analysis of the randomised, double-blind, placebo-controlled, phase 3 INBUILD trial. Respir Med. 2021;187:106574. doi:10.1016/j.rmed.2021.106574
26. Cottin V, Martinez FJ, Jenkins RG, et al. Safety and tolerability of nintedanib in patients with progressive fibrosing interstitial lung diseases: data from the randomized controlled INBUILD trial. Respir Res. 2022;23(1):85. doi:10.1186/s12931-022-01974-2
27. Solomon JJ, Danoff SK, Woodhead FA, et al. Safety, tolerability, and efficacy of pirfenidone in patients with rheumatoid arthritis-associated interstitial lung disease: a randomised, double-blind, placebo-controlled, phase 2 study. Lancet Respir Med. 2023;11(1):87-96. doi:10.1016/S2213-2600(22)00260-0
28. Behr J, Prasse A, Kreuter M, et al. Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trial. Lancet Respir Med. 2021;9(5):476-486. doi:10.1016/S2213-2600(20)30554-3
29. King TE Jr, Bradford WZ, Castro-Bernardini S, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2083-2092. doi:10.1056/NEJMoa1402582
30. Tsubouchi K, Hirose M, Takei R, et al. Upfront combination therapy with nintedanib and anti-inflammatory agents for progressive pulmonary fibrosis: a multicenter, single-arm phase 2 study (TOP-ILD). ERJ Open Research. 2025:00697-2025. doi: 10.1183/23120541.00697-2025
31. Mansy L, Caille A, Reynaud-Gaubert M, et al. Rituximab and mycophenolate mofetil in interstitial lung disease (EVER-ILD): 1-year follow-up results of a randomised controlled trial. Eur Respir J. 2024;64(3):2401368. doi:10.1183/13993003.01368-2024
32. Tekgoz E, Colak SY, Gunes EC, Ocal N, Cinar M, Yilmaz S. Nintedanib and its combination with immunosuppressives in connective tissue disease-related interstitial lung diseases. Ir J Med Sci. 2025;194(1):391-397. doi:10.1007/s11845-024-03848-6
33. A. Mittal, P. Saiganesh, S. Dachert, S. Gayen, and A. Ajmeri. Combination Antifibrotic and Immunosuppressive Therapy for Myositis Associated Interstitial Lung Disease [abstract]. Am J Respir Crit Care Med 2025;211:A2631. doi:10.1164/ajrccm.2025.211.Abstracts.A2631
34. Dixon G, Hague S, Mulholland S, et al. Real-world experience of nintedanib for progressive fibrosing interstitial lung disease in the UK. ERJ Open Res. 2024;10(1):00529-2023. doi:10.1183/23120541.00529-2023
35. Wang J, Wang X, Qi X, et al. The Efficacy and Safety of Pirfenidone Combined With Immunosuppressant Therapy in Connective Tissue Disease-Associated Interstitial Lung Disease: A 24-Week Prospective Controlled Cohort Study. Front Med (Lausanne). 2022;9:871861. doi:10.3389/fmed.2022.871861
36. Shen L, Yan Q, Chen X. Efficacy of Combination Therapy With Pirfenidone and Low-Dose Cyclophosphamide for Refractory Interstitial Lung Disease Associated With Connective Tissue Disease: A Case-Series of Seven Patients. Arch Rheumatol. 2019;35(2):180-188. doi:10.46497/ArchRheumatol.2020.7381
37. Yanagihara T, Suzuki K, Egashira A, et al. Nintedanib and intensive immunosuppressive therapy to treat rapidly progressive interstitial lung disease presenting anti-ARS antibodies. Respir Med Case Rep. 2020;31:101272. doi:10.1016/j.rmcr.2020.101272
38. Zhu L, Chung MP, Gagne L, et al. Rituximab Versus Mycophenolate in the Treatment of Recalcitrant Connective Tissue Disease-Associated Interstitial Lung Disease. ACR Open Rheumatol. 2021;3(1):3-7. doi:10.1002/acr2.11210
39. Kondoh Y, Ito T, Kimura H, Bao H, Kuwana M. Patient characteristics and pharmacologic treatment patterns in antifibrotic-treated patients with fibrosing interstitial lung diseases: real-world results from a claims database. BMC Pulm Med. 2025;25(1):253. doi:10.1186/s12890-025-03713-x
40. Hisata S, Bando M, Homma S, et al. Safety and tolerability of combination therapy with pirfenidone and nintedanib for idiopathic pulmonary fibrosis: A multicenter retrospective observational study in Japan. Respir Investig. 2021;59(6):819-826. doi:10.1016/j.resinv.2021.04.005
41. Taniguchi H, Ogura T, Inoue Y, Akimoto M, Azuma A. Long-term safety of combination therapy with nintedanib and pirfenidone in Japanese patients with IPF. Eur Resp J. 2016;48(suppl 60):PA2089. doi:10.1183/13993003.congress-2016.PA2089
42. Kou M, Jiao Y, Li Z, et al. Real-world safety and effectiveness of pirfenidone and nintedanib in the treatment of idiopathic pulmonary fibrosis: a systematic review and meta-analysis. Eur J Clin Pharmacol. 2024;80(10):1445-1460. doi:10.1007/s00228-024-03720-7
43. Wang T, Cui Z, Ou Y, et al. Post-marketing safety concerns with pirfenidone and nintedanib: an analysis of individual case safety reports from the FDA adverse event reporting system database and the Japanese adverse drug event report databases. Front Pharmacol. 2025;16:1530697. doi:10.3389/fphar.2025.1530697
44. Loveman E, Copley VR, Colquitt JL, et al. The effectiveness and cost-effectiveness of treatments for idiopathic pulmonary fibrosis: systematic review, network meta-analysis and health economic evaluation. BMC Pharmacol Toxicol. 2014;15:63. doi:10.1186/2050-6511-15-63
45. Westerink L, Nicolai JLJ, Postma MJ, van Boven JFM, Boersma C. Cost-Effectiveness of Nintedanib for Patients with Progressive Fibrosing Interstitial Lung Disease (PF-ILD). Pharmacoecon Open. 2022;6(5):647-656. doi:10.1007/s41669-022-00354-2
46. Kattih Z, Greenstein Z, Makkar P, Gupta R. Advanced interstitial lung disease: Evidence-based management and clinical approach. Sarcoidosis Vasc Diffuse Lung Dis. 2025 Jun 25;42(2):16206. doi: 10.36141/svdld.v42i2.16206. PMID: 40699491; PMCID: PMC12242865.
47. Ruaro B, Baratella E, Confalonieri P, Wade B, Marrocchio C, Geri P, Busca A, Pozzan R, Andrisano AG, Cova MA, Confalonieri M, Salton F. High-Resolution Computed Tomography: Lights and Shadows in Improving Care for SSc-ILD Patients. Diagnostics (Basel). 2021 Oct 22;11(11):1960. doi: 10.3390/diagnostics11111960. PMID: 34829307; PMCID: PMC8617987.
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Ryan Fischer, Khawaja Abdul Rehman
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Transfer of Copyright and Permission to Reproduce Parts of Published Papers.
Authors retain the copyright for their published work. No formal permission will be required to reproduce parts (tables or illustrations) of published papers, provided the source is quoted appropriately and reproduction has no commercial intent. Reproductions with commercial intent will require written permission and payment of royalties.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
